- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about RHHBY
Recent news which mentions RHHBY
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
December 06, 2023
From Benzinga
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
December 05, 2023
From Benzinga
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
December 05, 2023
From Benzinga
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
December 04, 2023
From Benzinga
From Benzinga
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
December 04, 2023
From Benzinga
Ignore Crypto: These Stocks Could Make You Rich
November 23, 2023
From Motley Fool
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
November 17, 2023
From InvestorPlace
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
From Benzinga
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
November 10, 2023
From Motley Fool
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
November 02, 2023
From Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
October 31, 2023
From Benzinga
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
October 28, 2023
From Benzinga
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
October 28, 2023
From Motley Fool
From Motley Fool
Why Is Roivant Sciences (ROIV) Stock Up Today?
October 23, 2023
From InvestorPlace
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
October 23, 2023
From Benzinga
Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion
October 23, 2023
From MarketWatch
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
October 21, 2023
From Motley Fool
From MarketWatch
From Benzinga
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
October 17, 2023
From Benzinga
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
October 17, 2023
From Benzinga
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
October 16, 2023
From Benzinga
Tempest Therapeutics shares head back to earth after 4,000% gain
October 12, 2023
From MarketWatch
TPST Stock: 7 Things to Know About Tempest Therapeutics
October 11, 2023
From InvestorPlace
From Benzinga
From MarketWatch
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.